Humans cannot hear bodily noises, yet they contain clinically significant data that can aid in the diagnosis of clinical disorders. This critical information was previously unavailable. Listening to these inaudible bodily sounds yields critical medical insights, and a new technology integrates AI to provide illness classification for cardiopulmonary disorders such as COPD, pneumonia, asthma, and cardiac morbidities.
“FDA clearance is an important milestone for Sanolla. The VoqX, which has been used extensively for studies in the United States, Europe and Israel, is now available for clinical use,”
Dr. Doron Adler, Sanolla’s co-founder and CEO.
Sanolla (Nesher, Israel) has released the AI-ready VoqX, the world’s first stethoscope that can listen to infrared acoustic waves that humans cannot hear. Sanolla’s smart infrared stethoscope has the potential to replace all current archaic-technology stethoscopes. Sanolla’s innovative technology, entitled “The Sounds of Life,” detects clinically rich low-frequency sound waves (3–40Hz), also known as infrasound, that are not perceptible to the human ear but carry diagnostic information beyond what is available exclusively in the audible spectrum. The VoqX’s sophisticated signal processing transfers sounds to the most sensitive frequency range of the ear, which, when combined with dynamic noise cancellation, gives an unparalleled audible experience.
VoqX collects infrared and audible noises, recognizes clinical conditions using AI algorithms, and displays diagnoses using its patented sound signature image. This can decrease the need for CT or X-ray radiation, as well as invasive blood testing, while also providing healthcare practitioners with a precise, quick diagnosis. Sanolla has created AI disease classification algorithms that give unrivaled illness categorization for numerous cardiopulmonary disorders such as COPD, pneumonia, asthma, and cardiac morbidities. The AI algorithms make extensive use of the infrared data that will be transferred to the AI-ready VoqX after it has received regulatory approval. The company has applied for 20 patents, eight of which have already been approved. Following the Israeli Health Ministry’s recent regulatory approval, Sanolla has received FDA 510 (k) authorization for the clinical usage of the AI-ready VoqX. The regulatory approvals allow Sanolla to make the VoqX available for clinical usage in the United States and Israel right away.
“The FDA approval is a significant step forward for Sanolla. The VoqX, which has been extensively utilized for research in the US, Europe, and Israel, is now accessible for clinical usage. Sanolla’s co-founder and CEO, Dr. Doron Adler, stated
“The VoqX is a fantastic instrument for identifying cardiac morbidities, including valve diseases,” stated Dr. Michael Wasserman, MD, a geriatric care expert who serves on federal and state advisory panels. Its acoustic optimization and dynamic noise cancellation make the VoqX an invaluable tool for physicians in any situation, and it is predicted to increase general practitioners’ early diagnosis of heart and lung problems at the primary care level.
